Previous studies suggest that PD-L1 expression can be a potential biomarker for efficacy of NSCLC treatment including surgery, radiotherapy and checkpoint inhibition [19, 21, 30–32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.